Member Info for Ghia

This is going to be common place moving forward. The value of SNG001 is priceless with it being agnostic to mutations.

Countless articles published recently suggesting latest mabs are ineffective against new Brazil variants.

Vaccine effectiveness faltering against variants.

We need SNG001 as the reactive treatment and continual vaccine development as the targeted seasonal boosters.

I suspect when they expand trials to more risky patients they may come a cropper. Corticosteroids can suppress the immune response if given too early it could cause more harm than good.

SNG001 suppresses the virus so is a much safer bet for early use.

Apart from the fact SNG will be efficiently mass produced.

The pricing conversation is pointless to have right now.

The fact is the cost to produce SNG001 will be on par with other medicines.

What SNG end up charging will be dependant on the strength of the data and the value proposition it presents to the markets.

There will be a sweet spot and I trust RM will hit that.

He has been very non comital ref pricing thus far even suggesting the cost will vary depending on target market.

Simply ruling it out based on being too expensive is a bit naive.

If that’s the bar that has been set SNG001 should have no problem achieving better results.

At what point do SNG supply Activ2 with a look at the HT data.

Could this already be going on?

I’m not invested in NCYT currently but having read the RNS I think once the dust settles things will recover a bit.

Clearly there is a dispute ref a contract that expired end of last year, but there may be a legal route to recoup that revenue.

They delivered product in Q1 to the same customer, it however seems this shipment may fulfil the demand from that customer for the remainder of 2021.

Sounds to me that the customer is happy with the promate product but covid rates falling will lessen demand in that area. So only expect further sales in 2021 to them if rates increase in the 2nd half of the year.

The testing market is pivoting clearly towards the private sector to facilitate travel and hospitality needs. This makes up 50% of the Q1 2021 revenue and is a market that will grow in size.

NCYT are well placed to take a chunk of this market margins may get squeezed but the margin was pretty healthy to begin with.

Don’t forget the wedge of cash they are sitting on enviable position to be in.

Nova is probably a good buy once the dust settles

Today’s SP action, is just that SP action. The commentary last night was on the whole constructive and balanced.

I transacted a bed and ISA via phone yesterday I was thrilled to achieve a sell at 158.75 and a buy 159. That spread is much tighter than what was published on these boards.

I note this mornings spread was 1.5% the delayed prices displayed do not often depict what is actually going on.

Kevin - I think you mean the P3 hospital trial Sprinter which is 610 patients globally.

Activ2 is 200ish outpatients for P2 and then a larger cohort if it advances to P3.

I would think P3 is well on its way to filling in the U.K., Europe and the US are just starting to come on board so a few months yet until we can get excited about those results.

Trek - As expected a balanced view for you.

One question I have why are you more excited by Activ2 data over HT?

If anything the cohort of patients on Activ2 will be even more difficult since it is open to anyone over the age of 18.

I’m not particularly concerned by either trial as I think the body of data is growing and agencies will be pragmatic enough to look at the whole picture certainly Activ2 states they are happy to look at supporting results.

Remember the video was recorded a month ago if RM had the HT results to hand at that point he would not have been allowed to sit on it since for a month.

He’s just managing expectations.

Was this conference today or a pre-recording?

Comments are clearly expectation management, the challenge of HT is that the placebo arm will be strong, that was known from the beginning and a small trial it will be hard to get a statistically significant result.

Seeing SNG001 being used in trials globally puts a massive smile on my face.

I bet Holgate is starting to feel rather proud of his baby and rightly so!

I’m hoping HT results will be enough to push for EUA. Success at P3 will bring full approval.

The most important thing for SNG is to achieve approval this summer.

Demand for therapeutics next autumn winter will be huge. Everything becomes easier with approval.

Yep very good news indeed clear sign they are not going to try and pull a fast one and ignore IP due to a state of emergency.

They also seem to like IFN.

Kevin - If bad news is on the horizon why would they only sell a measly 0.125% that’s hardly covering their potential losses.

Most likely reason IMO is a slight adjustment of portfolio for the new fiscal year

Chuck the URL into google cache archive and you will see what changed and when.

Felldown- More importantly they used language such as should and we hope up until the point that they had concrete scientific proof that it works.

Now the language is very much it works and we are jumping through the hoop to prove this in larger numbers.

Not always right but today was a welcome exception.

This share certainly gives everyone a fighting chance of a good entry.

I remember saying last year "if you are late to the party you should have to pay more" it seems like SNG has a ban on all ticket touts and you pay RRP or special flash crash bonus deals for your ride...

We may finish blue today lots of appetite for buying at this price, nothing would surprise me currently.